DEF 14A: Haemonetics Announces Details for 2024 Annual Shareholder Meeting

Haemonetics Corporation has released its proxy statement outlining the agenda for its 2024 Annual Meeting of Shareholders, including the election of directors, executive compensation, and ratification of the independent auditor.

Summary

• Haemonetics Corporation will hold its 2024 Annual Meeting of Shareholders on July 25, 2024, in Boston.
• Shareholders will vote on electing nine director nominees, approving executive compensation on an advisory basis, and ratifying the appointment of Ernst & Young LLP as the independent auditor for fiscal year 2025.
• The company encourages shareholders to vote via the Internet, telephone, or mail.
• Haemonetics had a positive fiscal year 2024, experiencing strong demand for its products despite a challenging macroeconomic environment.
• The company's revenue was $1.309 billion, with adjusted earnings per share of $3.96.
• Free cash flow before restructuring and RRC was $127.2 million, and the adjusted operating margin was 21.1%.
• The Board recommends voting FOR all director nominees, the advisory vote on executive compensation, and the ratification of Ernst & Young LLP.
• The company is committed to transparent engagement with its shareholders, with board members offering meetings to discuss governance and executive compensation matters.
• Haemonetics' corporate responsibility programs focus on environmental, social, and governance (ESG) risks and opportunities.
• The Compensation Committee focuses on total direct compensation, including base salary, short-term incentives, and long-term incentives, to align executive interests with shareholder value.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting strong financial results and strategic achievements. However, it also acknowledges challenges and risks, resulting in a moderately positive sentiment score.

Positives

• Haemonetics experienced strong demand for its products in fiscal 2024.
• The company delivered high-teens organic revenue growth in the Hospital segment.
• Haemonetics is on track to deliver increased value to customers and shareholders.
• The company maintains strong executive compensation governance and pay practices.
• Haemonetics has received over 94% say-on-pay approval from shareholders for the last nine years.
• The company has an independent Board Chair and directors.
• The company has annual election of directors.
• The company has regular executive sessions of independent directors.
• The company has Board oversight of risk management and compliance.
• The company has annual Board and standing committee evaluations, including individual Board member peer review.
• The company has guidelines to promote refreshment, including age 75 retirement and average director tenure of ten years or less.
• The company has transparent and active shareholder engagement.
• The company has annual say-on-pay advisory vote, with over 94% approval in each of the last nine years.
• The company has majority voting provisions in Charter and By-Laws.
• The company has shareholder right to call special meetings.
• The company has director resignation policy if a director does not obtain a majority of the votes cast in an uncontested election.
• The company has no shareholder rights plan (i.e., a 'poison pill').
• The company maintains strong executive compensation governance and pay practices.

Risks

• The company acknowledges a challenging and uncertain macroeconomic environment.
• The company's three-year cumulative total shareholder return was affected by a substantial share price decrease in April 2021 following the announcement of a key customer loss.

Future Outlook

Haemonetics remains on track to deliver increased value to customers and shareholders, targeting transformational growth, diversification, and sustainability in its business.

Industry Context

Haemonetics operates in the global healthcare industry, providing medical technology solutions for blood and plasma component collection, the surgical suite, and hospital transfusion services. The company competes with other medical device manufacturers and service providers in these markets.

Comparison to Industry Standards

• The document mentions a peer group of companies used for setting executive compensation, including Avanos Medical, Bruker Corporation, Integra LifeSciences, and others.
• Haemonetics' revenue and market capitalization are compared to the 50th percentile of this peer group.
• The company's three-year total shareholder return is compared to the S&P MidCap 400 Index.
• The company's total shareholder return is compared to the S&P Health Care Equipment Select Industry Index.

Stakeholder Impact

• Shareholders are encouraged to participate in the voting process.
• The company's performance and compensation programs are designed to align with shareholder interests.
• The company's corporate responsibility programs aim to benefit the environment, society, and governance.

Next Steps

• Shareholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will announce the preliminary voting results at the Annual Meeting.
• The final voting results will be published in a Current Report on Form 8-K.

Key Dates

Keywords

shareholders, executive compensation, directors, annual meeting, proxy statement, Haemonetics, governance, audit